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Implantable defibrillators:
from a pioneering idea to an
evidence-based treatment
The story of the implantable cardioverter-defibrillator (ICD) as an
effective tool for reducing sudden death and improving survival in
appropriately selected patients has never been simple and since the
pioneering era of Michel Mirowski1 has always been the subject of
debate and controversy. In the last 15 years, randomized clinical
trials and, as a consequence, evidence-based international guide-
lines have extended the clinical application of ICDs to increasingly
broad patient populations, not only in the setting of secondary pre-
vention of sudden cardiac death, but also in the setting of primary
sudden cardiac death prevention (i.e. for patients who are identi-
fied as being at risk of life-threatening ventricular tachyarrhythmias,
despite no previous history of these events).2,3 However, primary
prevention is a particularly challenging area, as many years may pass
before the benefits of the intervention can be perceived within
the targeted population, and the financial burden of widespread
implementation of such indications may constitute an important
limitation in some economic settings.3,4 Recently, the results of
the DANISH trial,5 focused on ICD implant for primary prevention
in patients with non-ischaemic cardiomyopathy, appear to increase
the uncertainty on the role of ICD for extending survival and stim-
ulated a new debate on ICD benefit.
Implantable cardioverter-
defibrillators in the setting
of ischaemic and non-ischaemic
cardiomyopathies
The benefits of ICDs implanted for primary prevention of sud-
den death in patients with left ventricular dysfunction were
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. initially demonstrated in patients with previous myocardial
infarction (MADIT I, MUSTT, MADIT II trials),3 and were then
extended to patients with left ventricular dysfunction and heart
failure [New York Heart Association (NYHA) classes II and III] of
either ischaemic or non-ischaemic aetiology on the basis of the
results of the SCD-HeFT trial.2,6 In all these studies, the primary
endpoint was all-cause mortality and this appears absolutely
justified as no doubts can arise from using a hard endpoint that
is independent of definitions and not affected by the availability
or non-availability of specific data related to the terminal event.
Moreover, the assumption that prevention of arrhythmic death
translates in reduction in all-cause mortality is not always true,
as demonstrated in the two trials that evaluated the ICD in the
setting of a recent myocardial infarction (IRIS and DINAMIT).7,8
Both in IRIS and DINAMIT the reduction in sudden death in
ICD patients was completely offset by increased non-arrhythmic
deaths, thus resulting in no impact on all-cause mortality.7,8
Between 2002 and 2005, in the phase of validation of ICD
therapy for primary prevention of sudden cardiac death with ran-
domized controlled trials (RCTs), the setting of non-ischaemic
cardiomyopathy was not prioritized in comparison with the set-
ting of ischaemic heart disease. Indeed, CAT and AMIOVIRT were
studies with a small sample size (<120 patients in each study)
and were underpowered to demonstrate a mortality benefit.9 The
trial with the largest number of patients, the SCD-HeFT trial,
included both ischaemic and non-ischaemic patients (although a
separate analysis was pre-planned).6 The results of SCD-HeFT
showed that the benefit of ICD on all-cause mortality demon-
strated in the whole cohort did not reach statistical signifi-
cance in the non-ischaemic subgroup [hazard ratio (HR) 0.73;
97.5% confidence interval (CI) 0.50–1.07; P= 0.06].5 Moreover,
a difference in ICD benefit was found according to NYHA
class, as ICD efficacy was demonstrated in NYHA class II,
but not in NYHA class III.6 The DEFINITE trial included 458
patients with non-ischaemic dilated cardiomyopathy, but the effect
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on all-cause mortality of ICD treatment was non-significant, as
compared with the control, despite the significant reduction of
sudden death.10
A meta-analysis including CAT, AMIOVERT, DEFINITE and the
non-ischaemic cohort of SCD-HeFT found a statistically signifi-
cant benefit of ICD therapy on all-cause mortality (relative risk
0.74; 95% CI 0.58–0.96; P= 0.02)11 and this was the basis for the
recommendations of international consensus guidelines.12,13 How-
ever, on the basis of data from these trials, the NICE guidelines
on ICD use issued in 2006 did not cover the use of ICDs for
non-ischaemic cardiomyopathy,14 a decision that was more recently
revised, including non-ischaemic cardiomyopathy among the indi-
cations for an ICD for primary prevention, in the presence of left
ventricular dysfunction and heart failure.1 The Danish Cardiac Soci-
ety also limited the indication for ICD in primary prevention to
ischaemic patients but, in parallel, promoted a randomized study,
the DANISH trial.5
The DANISH trial: impact
on general knowledge of the
benefits of implantable
cardioverter-defibrillators
The DANISH trial, published in 2016,5 evaluated the impact of
ICD implant in the setting of symptomatic heart failure with
systolic dysfunction (left ventricular ejection fraction ≤35%) due
to non-ischaemic cardiomyopathy. In a follow-up of more than
5.5 years, no survival benefit emerged in the ICD group as com-
pared with usual care in the entire population (HR 0.87; 95% CI
0.68–1.12, P= 0.28), although a significant reduction in the risk of
all-cause mortality was found in the subgroup of patients younger
than 68 years, with a 36% relative risk reduction (HR 0.64; 95% CI
0.45–0.90, P= 0.01). It is noteworthy that 58% of patients received
cardiac resynchronization therapy (CRT) but no significant inter-
action was found on ICD effects. In this study, sudden cardiac
death was actually significantly reduced by the ICD in the whole
group assigned to ICD treatment, as it was halved as compared
with controls (HR 0.50; 95% CI 0.31–0.82, P= 0.005), but sud-
den cardiac death accounted for only 35% of all-cause mortality
in the control group. Overall, 31% of deaths were attributed to
non-cardiovascular causes (36% in the ICD group and 27% in the
control group) and this type of death could have represented a
competing risk with sudden cardiac death, with a much higher
influence in the elderly, in whom multiple co-morbidities could pre-
sumably affect outcomes.
The findings of the DANISH trial on the age dependency of
ICD benefit need to be considered within the overall scenario
of evidence provided by the other randomized trials on ICDs in
primary prevention. Figure 1 provides an analysis of the efficacy of
ICD vs. control in the setting of primary prevention in patients
with heart failure, including all the randomized trials where the
efficacy on all-cause mortality was analysed, stratified by age. The
stratification by age, as shown in Figure 1, was done by considering



















































































.. younger patients. The meta-analysis that we performed according
to a random-effects model and that we present in Figure 1 shows
that the benefit of ICD on all-cause mortality is confirmed in
younger patients (< 65–70 years) with a relative risk reduction
of 32%, with important statistical significance. This meta-analysis,
including both patients with ischaemic and non-ischaemic aetiology,
highlights the contribution of the DANISH trial, as the benefit of
ICD treatment in the elderly is no longer detectable, as compared
with a previous meta-analysis,16 performed before the DANISH
trial. This situation is absolutely clear in the sensitivity analysis
that we report in the supplementary material online, Appendix S1,
in which the removal of every specific study never affected the
estimated efficacy of ICDs in younger patients, while removal
of the DANISH trial completely changed the estimated effect of
ICDs in the elderly (moving from no effect to beneficial). Recently
a meta-analysis focused only on non-ischaemic cardiomyopathy
and therefore limited to DEFINITE10 and DANISH5 trials similarly
showed that the use of ICDs in primary prevention was associated
with a significant benefit on all-cause mortality in younger, but
not in older, patients.17 Other recently published meta-analyses
updated the evaluation of ICD efficacy in the setting of primary
prevention of sudden death for non-ischaemic cardiomyopathy18,19
and found that overall the efficacy of ICD was confirmed even after
inclusion of the DANISH trial, but the investigators did not include
an analysis stratified by patient age.
Pharmacological treatments
and the concept of ‘optimized
medical treatment’
Any controlled evaluation of the efficacy of ICD in patients with
left ventricular systolic dysfunction and heart failure has to con-
sider that a series of drugs exerts favourable effects on outcome
that also include a reduction in the risk of sudden death.20 As
known, these agents include beta-blockers, angiotensin-converting
enzyme inhibitors, angiotensin receptor blocking agents, and aldos-
terone antagonists, and the evolution of evidence has led, with
time, to consider these agents as essential components of the ‘opti-
mized medical treatment’ that should be applied to any patient
with systolic dysfunction, thus proposing the ICD implant as a way
to reduce the residual risk of sudden cardiac death.20,21 The full
implementation of all these agents in daily practice occurred with
time and was often not fully complete or variable, when consid-
ering that the trials evaluating ICD efficacy that were published
around 15 years ago compared with most recent trials. It is possible
that differences in pharmacological treatments may explain at least
part of the heterogeneity found for the elderly in the meta-analysis
that we performed on the efficacy of ICDs on all-cause mortal-
ity (Figure 1). Other meta-analyses have also found some hetero-
geneity in ICD efficacy.19,22 According to recent data from the
PARADIGM-HF trial,23 treatment with sacubitril/valsartan is asso-
ciated with a reduction in both sudden cardiac death and death
from worsening heart failure as compared with enalapril; this evi-
dence further updates the composition of ‘optimized medical treat-
ment’ for patients with left ventricular systolic dysfunction.24,25
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Figure 1 Meta-analysis (performed by the authors according to a random-effects model) including literature data on implantable
cardioverter-defibrillators (ICDs) in the setting of primary prevention of sudden cardiac death, with estimate of the efficacy on all-cause
mortality vs. control, stratified by age (≥65–70 vs. < 65–70). The trials that enrolled patients with ischaemic heart disease are in red, the trials
that enrolled patients with non-ischaemic cardiomyopathies are in green and the trials including both aetiologies are in blue. A significant benefit
of ICD vs. controls is found in younger patients, but not in older patients. In older patients there is a significant heterogeneity of the effect of
ICD on all-cause mortality. The sensitivity analysis is reported in the supplementary material online, Appendix S1. CI, confidence interval; SE,
standard error.
Finally, the evaluation of more than 40 000 patients with heart
failure with systolic dysfunction, enrolled in 12 trials and performed
over the last 20 years showed that rates of sudden death have
declined substantially over time, a finding consistent with the cumu-
lative benefit of evidence-based medications.26 Actually, we do not
know to what extent the benefit of ICD treatment found in ran-
domized trials performed 10–15 years ago are still valid in light
of the improvement in pharmacological and non-pharmacological
treatments (e.g. revascularization). This situation constitutes a lim-
itation to be considered when comparing most recent trials (i.e.
the DANISH trial) with previous trials. However, these limitations
are also important for any treatment applied to patients concur-
rently treated with other therapies that are subject to evolution
and improvement over time.
Interpretation of the DANISH
trial and clinical implications
The evidence of an important degree of age dependency for






























. co-morbidities are topical issues. Independently of the effects of
ICD treatment, variations in the causes of death at increasing
age deserve attention. Although the incidence of sudden death
slightly increases with age, the proportion of deaths with the
characteristics of sudden death diminishes markedly at increasing
age, as a result of non-arrhythmic cardiovascular causes of death
or even of non-cardiac causes of death.27
As a consequence of change in the prevailing determinants of
death at increasing age it is quite normal that the benefit of ICD
shows some age dependence. A meta-analysis of five RCTs on ICDs
showed that the benefit of ICD therapy is attenuated at increasing
age and that this finding may be related to an accompanying increase
in the burden of co-morbid illness, even in the quite selected setting
of RCTs.28
Co-morbidities are important determinants of outcomes
in heart failure patients. The importance of co-morbidities as
strong determinants of outcomes is also very clear in real-world
registries.29–31 In a regional registry from Italy that enrolled
consecutive patients implanted with ICD and CRT-D devices,
co-morbidities proved to be independent predictors of the risk
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Figure 2 Data from a regional registry in Italy. Long-term out-
come (Kaplan–Meier curve of survival free from death/cardiac
transplant) in patients implanted with an implantable cardioverter-
defibrillator (ICD) according to number and severity of
co-morbidities, as expressed by Charlson co-morbidity index
(CCI). Modified from Boriani et al.32.
of death or cardiac transplant32 (Figure 2). An analysis from the
Danish national registry reported that an increased burden of
co-morbidities was associated with increased mortality, with a
higher proportion of patients who died without ever having expe-
rienced ICD shocks to terminate ventricular tachyarrhythmias.33,34
Some temporal trends may also have an influence on the mode
of death, as a reduction in the proportion of cardiovascular vs.
non-cardiovascular causes of death was observed in the last three
decades among patients enrolled in trials on heart failure.35
The evaluation of the patient’s life expectancy and the potential
role of co-morbidities in reducing the benefit of a strategy, like the
ICD, that is merely able to terminate ventricular tachyarrhythmias
and therefore may potentially condition only arrhythmic deaths,
is a true clinical challenge. The most recent guidelines on the
management of ventricular tachyarrhythmias and prevention of
sudden cardiac death released by the European Society of Cardiol-
ogy reported that ICD therapy is recommended to reduce sudden
cardiac death in patients with symptomatic heart failure (NYHA
classes II and III) and left ventricular ejection fraction ≤35% after
≥3 months of optimal medical therapy, provided that the candidates
are expected to survive for at least 1 year with good functional
status.36 The indication to select candidates for ICD after a clinical
estimate resulting in at least 1 year of life expectancy with good



















































































.. difficulties in making a precise prediction of outcome. This aspect
is not addressed specifically in guidelines, leaving this difficult task
to an undefined clinical judgement. Moreover, an upper limit of
age for candidacy for ICD has never been suggested and this
situation leaves a great margin of variability in candidate selection.
It is noteworthy that the document on appropriate use criteria for
candidacy for ICD or CRT-D implant released by the American
College of Cardiology Foundation in collaboration with the Heart
Rhythm Society, written as a result of an evaluation by expert physi-
cians of a series of potential clinical scenarios, rated the implant of
an ICD for primary prevention of sudden death in patients with left
ventricular ejection fraction ≤30% on guideline-directed medical
therapy if the patient’s age was between 80 and 89 years as ‘may
be appropriate’. The same rating was released for patients aged
≥90 years in NYHA class II or III.37 The same document also rated
the implant of an ICD in a patient with chronic kidney disease on
dialysis as ‘may be appropriate’, a setting in which the high risk of
non-sudden death coupled with lack of specific evidence of benefit
make clinical decision-making very uncertain.38
It is highly probable that age acts as a surrogate measure for
the absence/presence of co-morbidities that may have a major
impact on survival and may condition competing risks with regard
to the risk of arrhythmic death. The additional impact of multi-
ple co-morbidities on outcomes is clearly shown by an analysis
of data from four ICD trials, showing that the benefit of ICD
treatment on mortality decreases with the increasing number of
co-morbidities.39 The Seattle Proportional Risk Score has been
found to predict the proportion of sudden vs. non-sudden death
and predict the benefit of ICD according to the estimated condi-
tional probability of sudden death.40 A greater relative ICD benefit
on sudden death and total mortality emerged in those patients
with a higher predicted proportion of mortality from sudden death.
This provides an interesting tool for improved patient targeting for
use of ICDs in primary prevention40 or for deciding whether CRT
should include, or not, the defibrillation capability.41 In addition, the
growing use of CRT associated with defibrillation,42 as well as the
growing adoption of subcutaneous ICDs that occurred in recent
years43 make assessment of the appropriate targeting of this spe-
cific type of implanted device necessary.
The results of the DANISH trial should, in our view, stimu-
late more studies dedicated to improving outcome prediction
in the elderly, as well as in any case of patients with multiple
co-morbidities, two settings in which the knowledge of just one
branch of medicine may make accurate estimation of the outcome
very difficult. In the case of elderly patients, decision-making
can be easy at the extremes of the grey zone. For instance,
ICD should obviously be considered in elderly patients with
non-ischaemic cardiomyopathy when biological age, in view of
lack of co-morbidities or functional impairment, conditions a
better outcome as compared with actual age. In contrast, severe
co-morbidities and age> 80 years should discourage the implant
of an ICD for primary prevention of sudden cardiac death. Multi-
disciplinary teams have been proposed for improvement of patient
management and decision-making in different settings and can
certainly have a role in proposing a multidimensional approach to
a complex decision on appropriate management of heart failure,
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including candidacy for ICD implant. In any case, the setting
of patients younger than 65–70 also has to be approached in
specific cases with the aid of a multidisciplinary team of experts.
Patients with muscular dystrophies with a high risk of respira-
tory insufficiency, patients with severe obesity or severe chronic
kidney disease, and patients with previous cancer treated with
chemotherapy are very problematic cases for physicians. The
activity of a multidisciplinary team should also include the evalu-
ation of the psychological aspects of ICD recipients in order to
minimize the risk of psychological distress that may derive from
ICD shocks or device-related complications.44 While a multidisci-
plinary assessment has been proposed in heart failure guidelines,45
its role in decision-making for ICD implant is not specifically
stressed.
In interpreting the results of the DANISH trial, the heterogene-
ity of non-ischaemic cardiomyopathy should also be a matter of
consideration. The wide spectrum of the disease, often genetically
determined,46 as well as the variable severity of the disease accord-
ing to aetiology47 condition, a variability in outcome, as compared
with ischaemic heart disease, may make it more difficult to pre-
cisely assess the benefit of ICD in the setting of left ventricular
dysfunction. Randomized trials are ongoing in order to assess the
incremental value of selecting candidates for ICDs on the basis of
quantification of myocardial fibrosis with cardiovascular magnetic
resonance imaging48 or using a scintigraphic assessment of sympa-
thetic innervation of the myocardium.49
Conclusions
The DANISH trial had the merit to explore the complex setting
of non-ischaemic cardiomyopathy by means of a RCT and this
aspect is of great value as, in this setting, the benefit of ICDs was
not well defined. Even if the picture is not completely clear, we
now have more specific information on how age may influence the
benefit of an ICD on all-cause mortality in the setting of primary
prevention of sudden cardiac death. Below the age of 65–70,
implantation of an ICD appears to be beneficial in non-ischaemic
cardiomyopathy according to the recommendations of current
guidelines, even if this is derived from subgroup analysis. Future
guidelines will have to focus on this point better in light of the
results of the DANISH trial, as well as the results of several
analysis derived from this study combined with the previous ones.
As age is only one component of patient characterization, it is
absolutely vital to improve outcome prediction according to more
detailed evaluations of patient status, in addition to age, and taking
into account renal function, diabetes, other co-morbidities and
functional status, especially when these factors appear to have a
major impact on outcomes. In these conditions, clinical judgement
may benefit from the contribution of experts who interact in
multidisciplinary teams. Finally, prospective registries targeted to
assess outcomes at 3–5 years and beyond can have an important
role in improving our knowledge and in providing the basis for
future trials targeted on specific groups of patients characterized by





















































































Additional Supporting Information may be found in the online
version of this article:
Appendix S1. Sensitivity analysis.
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